Abstract
We have measured the concentrations of substance P, somatostatin, homovanillic acid (HVA), vanillyl mandelic acid (VMA) and 5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal fluid (CSF) of six patients suffering from narcolepsy and 12 age- and gender-matched controls using high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA). Substance P and somatostatin were significantly decreased in our patients compared to controls (36.9 +/- 9.1 fmol/ml versus 52.5 +/- 9.9 fmol/ml, P < 0.05 and 30.3 +/- 7.8 fmol/ml versus 43.9 +/- 9.8 fmol/ml, P < 0.05, respectively). 5-HIAA (P < 0.05) and VMA (P < 0.05) were also significantly decreased. HVA was significantly increased (P < 0.01). The CSF concentrations of substance P and somatostatin correlated with the clinical parameters duration of disease (r = -0.68, P < 0.05 and r = -0.72, P < 0.05, respectively) and severity of cataplectic symptoms (r = -0.71, P < 0.05 and r = -0.78, P < 0.01). In addition, substance P correlated with the intensity of sleepiness and the frequency of day-sleep attacks (r = -0.69, P < 0.05 and r = -0.68, P < 0.05, respectively). Substance P affects the amount of dopamine release in the nigra-striatal region, and decreased amounts could contribu...Continue Reading
References
Jan 1, 1992·Neurology·S J KishO Hornykiewicz
Jun 1, 1991·Canadian Journal of Psychology·M Mamelak
Oct 1, 1988·Neuropeptides·H CramerB Renaud
Jan 1, 1986·Progress in Neurobiology·J Epelbaum
Jan 1, 1988·The International Journal of Neuroscience·R SandykE Labadie
Oct 1, 1988·The International Journal of Neuroscience·K M Smith, F L Cohen
Mar 1, 1983·Annals of Neurology·K F FaullJ D Barchas
Jan 1, 1983·Peptides·M E Hall, J M Stewart
Aug 20, 1984·Life Sciences·S P Watson
Dec 1, 1983·Neurology·C GuilleminaultJ van den Hoed
Nov 1, 1982·Neurology·J MontplaisirG Rémillard
Aug 25, 1995·European Journal of Pharmacology·S KhanA T Michael-Titus
Jan 1, 1995·Experimental Brain Research·K IkemotoH C Fibiger
Sep 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·J D ParkesG Dunn
Jan 1, 1994·Peptides·R D Myers
May 17, 1996·Neuroreport·M StrittmatterK Schimrigk
Citations
Feb 24, 2001·Mayo Clinic Proceedings·L E KrahnM H Silber
Jul 11, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·C FehrN Dahmen
Dec 18, 2002·Journal of Neurochemistry·Lilian Puebla, Eduardo Arilla-Ferreiro
Jul 4, 2001·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·S OvereemG J Lammers
Nov 17, 2009·Journal of Veterinary Internal Medicine·A Bathen-NöthenA Tipold
Jan 9, 2003·Pharmacogenomics·Mehdi Tafti, Yves Dauvilliers
Jul 5, 2005·Clinica Chimica Acta; International Journal of Clinical Chemistry·Jose E Martínez-Rodríguez, Joan Santamaria
Apr 16, 2008·Expert Opinion on Therapeutic Targets·Ahmet Ursavas
May 15, 2007·Chest·Ahmet UrsavasR Oktay Gozu
Oct 15, 2013·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Emmanuel BäckrydBjörn Gerdle
Aug 22, 2014·Sleep·Anja HolmSteen Gammeltoft
Aug 18, 2004·Behavioural Brain Research·Filipe S DuarteThereza C M De Lima
Oct 6, 2021·BMC Neurology·Cory J Goracke-PostleFrank J Symons